Antiemetic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
Albany, NY -- (SBWIRE) -- 08/08/2017 -- Nausea and vomiting are symptoms of some medical conditions like pregnancy, motion sickness, food poisoning, dizziness. They are also known to be the side effects of chemotherapy, radiation, anesthesia or opioid analgesics. Post-operative nausea and vomiting is one of the common complication after surgery whereas chemotherapy induced nausea and vomiting is the most feared side effect of chemotherapy.
Nausea and vomiting are not life threatening but may lead to other complications like weight loss, dehydration, erosion of the tooth and loss of appetite. If not treated they can interfere with the daily activity and can affect the quality of life. Nausea and vomiting are known as emesis and the drugs used in the management of nausea and vomiting are known as Antiemetic.
The Antiemetic drug market is segmented on the basis of drug class and geography. On the basis of class it is classified as 5-HT3 receptor antagonists, Dopamine antagonists, NK1 receptor antagonist, Antihistamines, Cannabinoids and Others. According to few studies carried out it was seen that 5-HT3 antagonist are found to be very effective preventing nausea and vomiting in chemotherapy and radiations. Recently U.S. Food and Drug Administration sanctioned Varubi (rolapitant -NK-1 receptor antagonist) to stop delayed phase chemotherapy-induced emesis.
It is accepted in adults and need to be given in combination with other antiemetic drugs that prevent emesis related with early and recurrence courses of vomit-inducing cancer chemotherapy. Domperidone leads the dopamine antagonists while Dronabinols is the biggest selling drug from Cannabinoid.
On the basis of the geography, the artificial organ market can be segmented into North America), Europe, Asia Pacific, Latin America and Rest of the World. Asia pacific has reported to be the fastest growing market due to large number of cancer patients.
Fill the form to gain deeper insights on this market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1513
The antiemetic drug market will grow strongly in the coming years due to the increasing number of cancer patients. Nausea and vomiting can result from surgery and radiation also but cancer induced nausea and vomiting are severe and disturbing. In chemotherapy more than 60% of patients suffer from nausea and vomiting. Chemotherapeutic agents such as Cisplatin and Carmustine causes nausea and vomiting in more than 90% of the patients. Also the research activities carried out to innovate the therapy are responsible to drive the market.
The lack of appropriate animal model to imitate the human reaction is a restraint for the antiemetic drug market. Use of novel drug deliveries and several drugs in the pipelines will act as an opportunity for the manufacturers and can increase the market share of antiemetic drugs.
Some of the major players in the antiemetic drug market are GlaxoSmithKline Pharmaceuticals Limited, Johnson & Johnson, Sanofi, Merck & Co., Novartis AG,Bristol-Myers Squibb, Astellas Pharma, Inc., Eli Lilly, Abbott, Cipla Ltd, Dr. Reddy's Laboratories Ltd, Baxter International, IPCA Labs and others.
About Transparency Market Research
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.